Mechanisms of hepatocellular carcinoma progression
|
摘要
Hepatocellular carcinoma(HCC) is the most common primary malignancy of the liver. It is the second leading cause of cancer-related deaths worldwide, with a very poor prognosis. In the United States, there has been only minimal improvement in the prognosis for HCC patients over the past 15 years. Details of the molecular mechanisms and other mechanisms of HCC progression remain unclear. Consequently, there is an urgent need for better understanding of these mechanisms. HCC is often diagnosed at advanced stages, and most patients will therefore need systemic therapy, with sorafenib being the most common at the present time. However, sorafenib therapy only minimally enhances patient survival. This review provides a summary of some of the known mechanisms that either cause HCC or contribute to its progression. Included in this review are the roles of viral hepatitis, non-viral hepatitis, chronic alcohol intake, genetic predisposition and congenital abnormalities, toxic exposures, and autoimmune diseases of the liver. Well-established molecular mechanisms of HCC progression such as epithelial-mesenchymal transition, tumor-stromal interactions and the tumor microenvironment, cancer stem cells, and senescence bypass are also discussed. Additionally, we discuss the roles of circulating tumor cells,immunomodulation, and neural regulation as potential new mechanisms of HCC progression. A better understanding of these mechanisms could have implications for the development of novel and more effective therapeutic and prognostic strategies, which are critically needed.
Hepatocellular carcinoma(HCC) is the most common primary malignancy of the liver. It is the second leading cause of cancer-related deaths worldwide, with a very poor prognosis. In the United States, there has been only minimal improvement in the prognosis for HCC patients over the past 15 years. Details of the molecular mechanisms and other mechanisms of HCC progression remain unclear. Consequently, there is an urgent need for better understanding of these mechanisms. HCC is often diagnosed at advanced stages, and most patients will therefore need systemic therapy, with sorafenib being the most common at the present time. However, sorafenib therapy only minimally enhances patient survival. This review provides a summary of some of the known mechanisms that either cause HCC or contribute to its progression. Included in this review are the roles of viral hepatitis, non-viral hepatitis, chronic alcohol intake, genetic predisposition and congenital abnormalities, toxic exposures, and autoimmune diseases of the liver. Well-established molecular mechanisms of HCC progression such as epithelial-mesenchymal transition, tumor-stromal interactions and the tumor microenvironment, cancer stem cells, and senescence bypass are also discussed. Additionally, we discuss the roles of circulating tumor cells,immunomodulation, and neural regulation as potential new mechanisms of HCC progression. A better understanding of these mechanisms could have implications for the development of novel and more effective therapeutic and prognostic strategies, which are critically needed.
Hepatocellular carcinoma(HCC) is the most common primary malignancy of the liver. It is the second leading cause of cancer-related deaths worldwide, with a very poor prognosis. In the United States, there has been only minimal improvement in the prognosis for HCC patients over the past 15 years. Details of the molecular mechanisms and other mechanisms of HCC progression remain unclear. Consequently, there is an urgent need for better understanding of these mechanisms. HCC is often diagnosed at advanced stages, and most patients will therefore need systemic therapy, with sorafenib being the most common at the present time. However, sorafenib therapy only minimally enhances patient survival. This review provides a summary of some of the known mechanisms that either cause HCC or contribute to its progression. Included in this review are the roles of viral hepatitis, non-viral hepatitis, chronic alcohol intake, genetic predisposition and congenital abnormalities, toxic exposures, and autoimmune diseases of the liver. Well-established molecular mechanisms of HCC progression such as epithelial-mesenchymal transition, tumor-stromal interactions and the tumor microenvironment, cancer stem cells, and senescence bypass are also discussed. Additionally, we discuss the roles of circulating tumor cells,immunomodulation, and neural regulation as potential new mechanisms of HCC progression. A better understanding of these mechanisms could have implications for the development of novel and more effective therapeutic and prognostic strategies, which are critically needed.
引文
1 Bray F,Ferlay J,Soerjomataram I,Siegel RL,Torre LA,Jemal A.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin 2018;68:394-424[PMID:30207593 DOI:10.3322/caac.21492]
2 Siegel RL,Miller KD,Jemal A.Cancer Statistics,2017.CA Cancer J Clin 2017;67:7-30[PMID:28055103 DOI:10.3322/caac.21387]
3 Ghouri YA,Mian I,Rowe JH.Review of hepatocellular carcinoma:Epidemiology,etiology,and carcinogenesis.J Carcinog 2017;16:1[PMID:28694740 DOI:10.4103/jcar.JCar_9_16]
4 Golabi P,Fazel S,Otgonsuren M,Sayiner M,Locklear CT,Younossi ZM.Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities.Medicine(Baltimore)2017;96:e5904[PMID:28248853 DOI:10.1097/MD.0000000000005904]
5 Medavaram S,Zhang Y.Emerging therapies in advanced hepatocellular carcinoma.Exp Hematol Oncol2018;7:17[PMID:30087805 DOI:10.1186/s40164-018-0109-6]
6 Siegel RL,Miller KD,Jemal A.Cancer statistics,2018.CA Cancer J Clin 2018;68:7-30[PMID:29313949 DOI:10.3322/caac.21442]
7 Dimitroulis D,Damaskos C,Valsami S,Davakis S,Garmpis N,Spartalis E,Athanasiou A,Moris D,Sakellariou S,Kykalos S,Tsourouflis G,Garmpi A,Delladetsima I,Kontzoglou K,Kouraklis G.From diagnosis to treatment of hepatocellular carcinoma:An epidemic problem for both developed and developing world.World J Gastroenterol 2017;23:5282-5294[PMID:28839428 DOI:10.3748/wjg.v23.i29.5282]
8 Daher S,Massarwa M,Benson AA,Khoury T.Current and Future Treatment of Hepatocellular Carcinoma:An Updated Comprehensive Review.J Clin Transl Hepatol 2018;6:69-78[PMID:29607307DOI:10.14218/JCTH.2017.00031]
9 Ikeda M,Morizane C,Ueno M,Okusaka T,Ishii H,Furuse J.Chemotherapy for hepatocellular carcinoma:current status and future perspectives.Jpn J Clin Oncol 2018;48:103-114[PMID:29253194DOI:10.1093/jjco/hyx180]
10 Keating GM.Sorafenib:A Review in Hepatocellular Carcinoma.Target Oncol 2017;12:243-253[PMID:28299600 DOI:10.1007/s11523-017-0484-7]
11 Sanz-Cameno P,Trapero-Marugán M,Chaparro M,Jones EA,Moreno-Otero R.Angiogenesis:from chronic liver inflammation to hepatocellular carcinoma.J Oncol 2010;2010:272170[PMID:20592752DOI:10.1155/2010/272170]
12 Sampat KR,O'Neil B.Antiangiogenic therapies for advanced hepatocellular carcinoma.Oncologist 2013;18:430-438[PMID:23576483 DOI:10.1634/theoncologist.2012-0388]
13 Personeni N,Pressiani T,Santoro A,Rimassa L.Regorafenib in hepatocellular carcinoma:latest evidence and clinical implications.Drugs Context 2018;7:212533[PMID:30002715 DOI:10.7573/dic.212533]
14 Spallanzani A,Orsi G,Andrikou K,Gelsomino F,Rimini M,Riggi L,Cascinu S.Lenvatinib as a therapy for unresectable hepatocellular carcinoma.Expert Rev Anticancer Ther 2018;18:1069-1076[PMID:30220234 DOI:10.1080/14737140.2018.1524297]
15 Dhanasekaran R,Bandoh S,Roberts LR.Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances.F1000Res 2016;5[PMID:27239288 DOI:10.12688/f1000research.6946.1]
16 Tarocchi M,Polvani S,Marroncini G,Galli A.Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis.World J Gastroenterol 2014;20:11630-11640[PMID:25206269 DOI:10.3748/wjg.v20.i33.11630]
17 Ortega-Prieto AM,Dorner M.Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection.Vaccines(Basel)2017;5[PMID:28862649 DOI:10.3390/vaccines5030024]
18 Ramakrishna G,Rastogi A,Trehanpati N,Sen B,Khosla R,Sarin SK.From cirrhosis to hepatocellular carcinoma:new molecular insights on inflammation and cellular senescence.Liver Cancer 2013;2:367-383[PMID:24400224 DOI:10.1159/000343852]
19 Bartosch B,Thimme R,Blum HE,Zoulim F.Hepatitis C virus-induced hepatocarcinogenesis.J Hepatol2009;51:810-820[PMID:19545926 DOI:10.1016/j.jhep.2009.05.008]
20 Alzahrani B,Iseli TJ,Hebbard LW.Non-viral causes of liver cancer:does obesity led inflammation play a role?Cancer Lett 2014;345:223-229[PMID:24007864 DOI:10.1016/j.canlet.2013.08.036]
21 Sorrentino P,D'Angelo S,Ferbo U,Micheli P,Bracigliano A,Vecchione R.Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis.J Hepatol 2009;50:351-357[PMID:19070395 DOI:10.1016/j.jhep.2008.09.011]
22 Hann HW,Kim CY,London WT,Blumberg BS.Increased serum ferritin in chronic liver disease:a risk factor for primary hepatocellular carcinoma.Int J Cancer 1989;43:376-379[PMID:2538399]
23 Asare GA,Bronz M,Naidoo V,Kew MC.Synergistic interaction between excess hepatic iron and alcohol ingestion in hepatic mutagenesis.Toxicology 2008;254:11-18[PMID:18852013 DOI:10.1016/j.tox.2008.08.024]
24 Siriwardana RC,Niriella MA,Dassanayake A,Ediriweera D,Gunetilleke B,Sivasundaram T,de Silva J.Association of Serum Ferritin with Diabetes and Alcohol in Patients with Non-Viral Liver Disease-Related Hepatocellular Carcinoma.Liver Cancer 2017;6:307-312[PMID:29234634 DOI:10.1159/000477266]
25 Campbell PT,Newton CC,Freedman ND,Koshiol J,Alavanja MC,Beane Freeman LE,Buring JE,Chan AT,Chong DQ,Datta M,Gaudet MM,Gaziano JM,Giovannucci EL,Graubard BI,Hollenbeck AR,King L,Lee IM,Linet MS,Palmer JR,Petrick JL,Poynter JN,Purdue MP,Robien K,Rosenberg L,Sahasrabuddhe VV,Schairer C,Sesso HD,Sigurdson AJ,Stevens VL,Wactawski-Wende J,ZeleniuchJacquotte A,Renehan AG,Mc Glynn KA.Body Mass Index,Waist Circumference,Diabetes,and Risk of Liver Cancer for U.S.Adults.Cancer Res 2016;76:6076-6083[PMID:27742674 DOI:10.1158/0008-5472.CAN-16-0787]
26 Wei L,Li N,Wang G,Feng X,Lyu Z,Li X,Wen Y,Chen Y,Chen H,Chen S,Wu S,Dai M,He J.Waist Circumference Might Be a Predictor of Primary Liver Cancer:A Population-Based Cohort Study.Front Oncol 2018;8:607[PMID:30631750 DOI:10.3389/fonc.2018.00607]
27 Hu M,Phan F,Bourron O,FerréP,Foufelle F.Steatosis and NASH in type 2 diabetes.Biochimie 2017;143:37-41[PMID:29097281 DOI:10.1016/j.biochi.2017.10.019]
28 Yan G,Wang X,Sun C,Zheng X,Wei H,Tian Z,Sun R.Chronic Alcohol Consumption Promotes Diethylnitrosamine-Induced Hepatocarcinogenesis via Immune Disturbances.Sci Rep 2017;7:2567[PMID:28566719 DOI:10.1038/s41598-017-02887-7]
29 Ramadori P,Cubero FJ,Liedtke C,Trautwein C,Nevzorova YA.Alcohol and Hepatocellular Carcinoma:Adding Fuel to the Flame.Cancers(Basel)2017;9[PMID:28946672 DOI:10.3390/cancers9100130]
30 Ogunwobi OO,Puszyk W,Dong HJ,Liu C.Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma.PLo S One 2013;8:e63765[PMID:23723997 DOI:10.1371/journal.pone.0063765]
31 Singh AK,Kumar R,Pandey AK.Hepatocellular Carcinoma:Causes,Mechanism of Progression and Biomarkers.Curr Chem Genom Transl Med 2018;12:9-26[PMID:30069430 DOI:10.2174/2213988501812010009]
32 Kew MC.Aflatoxins as a cause of hepatocellular carcinoma.J Gastrointestin Liver Dis 2013;22:305-310[PMID:24078988]
33 Wu HC,Santella R.The role of aflatoxins in hepatocellular carcinoma.Hepat Mon 2012;12:e7238[PMID:23162603 DOI:10.5812/hepatmon.7238]
34 Tansel A,Katz LH,El-Serag HB,Thrift AP,Parepally M,Shakhatreh MH,Kanwal F.Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis:A Systematic Review and Metaanalysis.Clin Gastroenterol Hepatol 2017;15:1207-1217.e4[PMID:28215616 DOI:10.1016/j.cgh.2017.02.006]
35 Llovet JM,Zucman-Rossi J,Pikarsky E,Sangro B,Schwartz M,Sherman M,Gores G.Hepatocellular carcinoma.Nat Rev Dis Primers 2016;2:16018[PMID:27158749 DOI:10.1038/nrdp.2016.18]
36 Llovet JM,Montal R,Sia D,Finn RS.Molecular therapies and precision medicine for hepatocellular carcinoma.Nat Rev Clin Oncol 2018;15:599-616[PMID:30061739 DOI:10.1038/s41571-018-0073-4]
37 Brabletz T,Kalluri R,Nieto MA,Weinberg RA.EMT in cancer.Nat Rev Cancer 2018;18:128-134[PMID:29326430 DOI:10.1038/nrc.2017.118]
38 Kalluri R,Weinberg RA.The basics of epithelial-mesenchymal transition.J Clin Invest 2009;119:1420-1428[PMID:19487818 DOI:10.1172/JCI39104]
39 Lamouille S,Xu J,Derynck R.Molecular mechanisms of epithelial-mesenchymal transition.Nat Rev Mol Cell Biol 2014;15:178-196[PMID:24556840 DOI:10.1038/nrm3758]
40 Ye X,Weinberg RA.Epithelial-Mesenchymal Plasticity:A Central Regulator of Cancer Progression.Trends Cell Biol 2015;25:675-686[PMID:26437589 DOI:10.1016/j.tcb.2015.07.012]
41 Huaman J,Bach C,Ilboudo A,Ogunwobi OO,Liu C.Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma.Liu C.Precision Molecular Pathology of Liver Cancer.Cham:Springer International Publishing 2018;131-152
42 Puisieux A,Brabletz T,Caramel J.Oncogenic roles of EMT-inducing transcription factors.Nat Cell Biol2014;16:488-494[PMID:24875735 DOI:10.1038/ncb2976]
43 Tiwari N,Gheldof A,Tatari M,Christofori G.EMT as the ultimate survival mechanism of cancer cells.Semin Cancer Biol 2012;22:194-207[PMID:22406545 DOI:10.1016/j.semcancer.2012.02.013]
44 Chen L,Guo P,He Y,Chen Z,Chen L,Luo Y,Qi L,Liu Y,Wu Q,Cui Y,Fang F,Zhang X,Song T,Guo H.HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway.Cell Death Dis 2018;9:513[PMID:29725020 DOI:10.1038/s41419-018-0534-9]
45 Long L,Xiang H,Liu J,Zhang Z,Sun L.ZEB1 mediates doxorubicin(Dox)resistance and mesenchymal characteristics of hepatocarcinoma cells.Exp Mol Pathol 2019;106:116-122[PMID:30615851 DOI:10.1016/j.yexmp.2019.01.001]
46 Qu W,Wen X,Su K,Gou W.Mi R-552 promotes the proliferation,migration and EMT of hepatocellular carcinoma cells by inhibiting AJAP1 expression.J Cell Mol Med 2019;23:1541-1552[PMID:30597727DOI:10.1111/jcmm.14062]
47 Shi C,Chen Y,Chen Y,Yang Y,Bing W,Qi J.CD4+CD25+regulatory T cells promote hepatocellular carcinoma invasion via TGF-β1-induced epithelial-mesenchymal transition.Onco Targets Ther 2018;12:279-289[PMID:30643426 DOI:10.2147/OTT.S172417]
48 Xia C,Zhang XY,Liu W,Ju M,Ju Y,Bu YZ,Wang W,Shao H.LINC00857 contributes to hepatocellular carcinoma malignancy via enhancing epithelial-mesenchymal transition.J Cell Biochem2018[PMID:30506763 DOI:10.1002/jcb.28074]
49 Zhang B,Shi D,Zhang X,Liang G,Liu W,Qiao S.FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells.Oncol Lett 2018;16:7231-7238[PMID:30546461 DOI:10.3892/ol.2018.9541]
50 Das DK,Durojaiye V,Ilboudo A,Naidoo MK,Ogunwobi O.A"Patient-Like"Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis.J Vis Exp 2015;e52858[PMID:26555484 DOI:10.3791/52858]
51 Yang JD,Nakamura I,Roberts LR.The tumor microenvironment in hepatocellular carcinoma:current status and therapeutic targets.Semin Cancer Biol 2011;21:35-43[PMID:20946957 DOI:10.1016/j.semcancer.2010.10.007]
52 Delire B,Henriet P,Lemoine P,Leclercq IA,St?rkel P.Chronic liver injury promotes hepatocarcinoma cell seeding and growth,associated with infiltration by macrophages.Cancer Sci 2018;109:2141-2152[PMID:29727510 DOI:10.1111/cas.13628]
53 Affo S,Yu LX,Schwabe RF.The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer.Annu Rev Pathol 2017;12:153-186[PMID:27959632 DOI:10.1146/annurev-pathol-052016-100322]
54 Lu Y,Lin N,Chen Z,Xu R.Hypoxia-induced secretion of platelet-derived growth factor-BB by hepatocellular carcinoma cells increases activated hepatic stellate cell proliferation,migration and expression of vascular endothelial growth factor-A.Mol Med Rep 2015;11:691-697[PMID:25333351DOI:10.3892/mmr.2014.2689]
55 GalièM,Sorrentino C,Montani M,Micossi L,Di Carlo E,D'Antuono T,Calderan L,Marzola P,Benati D,Merigo F,Orlando F,Smorlesi A,Marchini C,Amici A,Sbarbati A.Mammary carcinoma provides highly tumourigenic and invasive reactive stromal cells.Carcinogenesis 2005;26:1868-1878[PMID:15975963 DOI:10.1093/carcin/bgi158]
56 Hernandez-Gea V,Toffanin S,Friedman SL,Llovet JM.Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.Gastroenterology 2013;144:512-527[PMID:23313965 DOI:10.1053/j.gastro.2013.01.002]
57 Friedman SL.Mechanisms of hepatic fibrogenesis.Gastroenterology 2008;134:1655-1669[PMID:18471545 DOI:10.1053/j.gastro.2008.03.003]
58 Amann T,Bataille F,Spruss T,Mühlbauer M,G?bele E,Sch?lmerich J,Kiefer P,Bosserhoff AK,Hellerbrand C.Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma.Cancer Sci 2009;100:646-653[PMID:19175606 DOI:10.1111/j.1349-7006.2009.01087.x]
59 Faouzi S,Lepreux S,Bedin C,Dubuisson L,Balabaud C,Bioulac-Sage P,Desmoulière A,Rosenbaum J.Activation of cultured rat hepatic stellate cells by tumoral hepatocytes.Lab Invest 1999;79:485-493[PMID:10212001]
60 Wang N,Wang S,Li MY,Hu BG,Liu LP,Yang SL,Yang S,Gong Z,Lai PBS,Chen GG.Cancer stem cells in hepatocellular carcinoma:an overview and promising therapeutic strategies.Ther Adv Med Oncol2018;10:1758835918816287[PMID:30622654 DOI:10.1177/1758835918816287]
61 Fransvea E,Paradiso A,Antonaci S,Giannelli G.HCC heterogeneity:molecular pathogenesis and clinical implications.Cell Oncol 2009;31:227-233[PMID:19478390 DOI:10.3233/CLO-2009-0473]
62 Williams GM,Gebhardt R,Sirma H,Stenb?ck F.Non-linearity of neoplastic conversion induced in rat liver by low exposures to diethylnitrosamine.Carcinogenesis 1993;14:2149-2156[PMID:8106178]
63 Bralet MP,Pichard V,Ferry N.Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosamine-treated rats.Hepatology 2002;36:623-630[PMID:12198654 DOI:10.1053/jhep.2002.35540]
64 Wu S,Powers S,Zhu W,Hannun YA.Substantial contribution of extrinsic risk factors to cancer development.Nature 2016;529:43-47[PMID:26675728 DOI:10.1038/nature16166]
65 Yavorkovsky L,Lai E,Ilic Z,Sell S.Participation of small intraportal stem cells in the restitutive response of the liver to periportal necrosis induced by allyl alcohol.Hepatology 1995;21:1702-1712[PMID:7539398]
66 Zhang Y,Bai XF,Huang CX.Hepatic stem cells:existence and origin.World J Gastroenterol 2003;9:201-204[PMID:12532431]
67 Mikhail S,He AR.Liver cancer stem cells.Int J Hepatol 2011;2011:486954[PMID:21994859 DOI:10.4061/2011/486954]
68 Jayachandran A,Dhungel B,Steel JC.Epithelial-to-mesenchymal plasticity of cancer stem cells:therapeutic targets in hepatocellular carcinoma.J Hematol Oncol 2016;9:74[PMID:27578206 DOI:10.1186/s13045-016-0307-9]
69 Machida K.Existence of cancer stem cells in hepatocellular carcinoma:myth or reality?Hepatol Int2017;11:143-147[PMID:27990610 DOI:10.1007/s12072-016-9777-7]
70 Jordan CT,Guzman ML,Noble M.Cancer stem cells.N Engl J Med 2006;355:1253-1261[PMID:16990388 DOI:10.1056/NEJMra061808]
71 Bonnet D,Dick JE.Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.Nat Med 1997;3:730-737[PMID:9212098]
72 Lapidot T,Sirard C,Vormoor J,Murdoch B,Hoang T,Caceres-Cortes J,Minden M,Paterson B,Caligiuri MA,Dick JE.A cell initiating human acute myeloid leukaemia after transplantation into SCIDmice.Nature 1994;367:645-648[PMID:7509044 DOI:10.1038/367645a0]
73 Cabrera MC,Hollingsworth RE,Hurt EM.Cancer stem cell plasticity and tumor hierarchy.World J Stem Cells 2015;7:27-36[PMID:25621103 DOI:10.4252/wjsc.v7.i1.27]
74 Pattabiraman DR,Weinberg RA.Tackling the cancer stem cells-what challenges do they pose?Nat Rev Drug Discov 2014;13:497-512[PMID:24981363 DOI:10.1038/nrd4253]
75 Thiery JP.Epithelial-mesenchymal transitions in tumour progression.Nat Rev Cancer 2002;2:442-454[PMID:12189386 DOI:10.1038/nrc822]
76 Wang T,Shigdar S,Gantier MP,Hou Y,Wang L,Li Y,Shamaileh HA,Yin W,Zhou SF,Zhao X,Duan W.Cancer stem cell targeted therapy:progress amid controversies.Oncotarget 2015;6:44191-44206[PMID:26496035 DOI:10.18632/oncotarget.6176]
77 Vu NB,Nguyen TT,Tran LC,Do CD,Nguyen BH,Phan NK,Pham PV.Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties.Cytotechnology 2013;65:491-503[PMID:23104270 DOI:10.1007/s10616-012-9511-9]
78 Rao S,Zaidi S,Banerjee J,Jogunoori W,Sebastian R,Mishra B,Nguyen BN,Wu RC,White J,Deng C,Amdur R,Li S,Mishra L.Transforming growth factor-βin liver cancer stem cells and regeneration.Hepatol Commun 2017;1:477-493[PMID:29404474 DOI:10.1002/hep4.1062]
79 Nio K,Yamashita T,Kaneko S.The evolving concept of liver cancer stem cells.Mol Cancer 2017;16:4[PMID:28137313 DOI:10.1186/s12943-016-0572-9]
80 Yoon SK.The biology of cancer stem cells and its clinical implication in hepatocellular carcinoma.Gut Liver 2012;6:29-40[PMID:22375168 DOI:10.5009/gnl.2012.6.1.29]
81 Yamashita T,Ji J,Budhu A,Forgues M,Yang W,Wang HY,Jia H,Ye Q,Qin LX,Wauthier E,Reid LM,Minato H,Honda M,Kaneko S,Tang ZY,Wang XW.Ep CAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features.Gastroenterology 2009;136:1012-1024[PMID:19150350 DOI:10.1053/j.gastro.2008.12.004]
82 Yang ZF,Ho DW,Ng MN,Lau CK,Yu WC,Ngai P,Chu PW,Lam CT,Poon RT,Fan ST.Significance of CD90+cancer stem cells in human liver cancer.Cancer Cell 2008;13:153-166[PMID:18242515DOI:10.1016/j.ccr.2008.01.013]
83 Ma S,Chan KW,Hu L,Lee TK,Wo JY,Ng IO,Zheng BJ,Guan XY.Identification and characterization of tumorigenic liver cancer stem/progenitor cells.Gastroenterology 2007;132:2542-2556[PMID:17570225 DOI:10.1053/j.gastro.2007.04.025]
84 Zhu Z,Hao X,Yan M,Yao M,Ge C,Gu J,Li J.Cancer stem/progenitor cells are highly enriched in CD133+CD44+population in hepatocellular carcinoma.Int J Cancer 2010;126:2067-2078[PMID:19711346 DOI:10.1002/ijc.24868]
85 Haraguchi N,Ishii H,Mimori K,Tanaka F,Ohkuma M,Kim HM,Akita H,Takiuchi D,Hatano H,Nagano H,Barnard GF,Doki Y,Mori M.CD13 is a therapeutic target in human liver cancer stem cells.JClin Invest 2010;120:3326-3339[PMID:20697159 DOI:10.1172/JCI42550]
86 Merle P,Trepo C.Molecular mechanisms underlying hepatocellular carcinoma.Viruses 2009;1:852-872[PMID:21994573 DOI:10.3390/v1030852]
87 Di Micco R,Fumagalli M,Cicalese A,Piccinin S,Gasparini P,Luise C,Schurra C,Garre'M,Nuciforo PG,Bensimon A,Maestro R,Pelicci PG,d'Adda di Fagagna F.Oncogene-induced senescence is a DNAdamage response triggered by DNA hyper-replication.Nature 2006;444:638-642[PMID:17136094 DOI:10.1038/nature05327]
88 Naugler WE,Karin M.NF-kappa B and cancer-identifying targets and mechanisms.Curr Opin Genet Dev2008;18:19-26[PMID:18440219 DOI:10.1016/j.gde.2008.01.020]
89 Van Antwerp DJ,Martin SJ,Kafri T,Green DR,Verma IM.Suppression of TNF-alpha-induced apoptosis by NF-kappa B.Science 1996;274:787-789[PMID:8864120]
90 Bassères DS,Baldwin AS.Nuclear factor-kappa B and inhibitor of kappa B kinase pathways in oncogenic initiation and progression.Oncogene 2006;25:6817-6830[PMID:17072330 DOI:10.1038/sj.onc.1209942]
91 Luo JL,Tan W,Ricono JM,Korchynskyi O,Zhang M,Gonias SL,Cheresh DA,Karin M.Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin.Nature 2007;446:690-694[PMID:17377533 DOI:10.1038/nature05656]
92 Hardy T,Mann DA.Epigenetics in liver disease:from biology to therapeutics.Gut 2016;65:1895-1905[PMID:27624887 DOI:10.1136/gutjnl-2015-311292]
93 Xiao Z,Shen J,Zhang L,Li M,Hu W,Cho C.Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma:Recent progress and future prospects.Oncol Lett 2018;15:3395-3402[PMID:29467864 DOI:10.3892/ol.2018.7758]
94 Peng L,Yuan XQ,Zhang CY,Peng JY,Zhang YQ,Pan X,Li GC.The emergence of long non-coding RNAs in hepatocellular carcinoma:an update.J Cancer 2018;9:2549-2558[PMID:30026854 DOI:10.7150/jca.24560]
95 Sia D,Villanueva A,Friedman SL,Llovet JM.Liver Cancer Cell of Origin,Molecular Class,and Effects on Patient Prognosis.Gastroenterology 2017;152:745-761[PMID:28043904 DOI:10.1053/j.gastro.2016.11.048]
96 LetouzéE,Shinde J,Renault V,Couchy G,Blanc JF,Tubacher E,Bayard Q,Bacq D,Meyer V,Semhoun J,Bioulac-Sage P,Prév?t S,Azoulay D,Paradis V,Imbeaud S,Deleuze JF,Zucman-Rossi J.Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis.Nat Commun 2017;8:1315[PMID:29101368 DOI:10.1038/s41467-017-01358-x]
97 Hagel M,Miduturu C,Sheets M,Rubin N,Weng W,Stransky N,Bifulco N,Kim JL,Hodous B,Brooijmans N,Shutes A,Winter C,Lengauer C,Kohl NE,Guzi T.First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.Cancer Discov 2015;5:424-437[PMID:25776529 DOI:10.1158/2159-8290.CD-14-1029]
98 Micalizzi DS,Maheswaran S,Haber DA.A conduit to metastasis:circulating tumor cell biology.Genes Dev 2017;31:1827-1840[PMID:29051388 DOI:10.1101/gad.305805.117]
99 Gallerani G,Fici P,Fabbri F.Circulating Tumor Cells:Back to the Future.Front Oncol 2017;6:275[PMID:28123996 DOI:10.3389/fonc.2016.00275]
100 van de Stolpe A,Pantel K,Sleijfer S,Terstappen LW,den Toonder JM.Circulating tumor cell isolation and diagnostics:toward routine clinical use.Cancer Res 2011;71:5955-5960[PMID:21896640 DOI:10.1158/0008-5472.CAN-11-1254]
101 Pantel K,Brakenhoff RH,Brandt B.Detection,clinical relevance and specific biological properties of disseminating tumour cells.Nat Rev Cancer 2008;8:329-340[PMID:18404148 DOI:10.1038/nrc2375]
102 Fan JL,Yang YF,Yuan CH,Chen H,Wang FB.Circulating Tumor Cells for Predicting the Prognostic of Patients with Hepatocellular Carcinoma:A Meta Analysis.Cell Physiol Biochem 2015;37:629-640[PMID:26344495 DOI:10.1159/000430382]
103 Li J,Han X,Yu X,Xu Z,Yang G,Liu B,Xiu P.Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma:circulating tumor cells and circulating tumor DNA.JExp Clin Cancer Res 2018;37:213[PMID:30176913 DOI:10.1186/s13046-018-0893-1]
104 Okajima W,Komatsu S,Ichikawa D,Miyamae M,Ohashi T,Imamura T,Kiuchi J,Nishibeppu K,Arita T,Konishi H,Shiozaki A,Morimura R,Ikoma H,Okamoto K,Otsuji E.Liquid biopsy in patients with hepatocellular carcinoma:Circulating tumor cells and cell-free nucleic acids.World J Gastroenterol 2017;23:5650-5668[PMID:28883691 DOI:10.3748/wjg.v23.i31.5650]
105 Schulze K,Gasch C,Staufer K,Nashan B,Lohse AW,Pantel K,Riethdorf S,Wege H.Presence of Ep CAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.Int J Cancer 2013;133:2165-2171[PMID:23616258 DOI:10.1002/ijc.28230]
106 von Felden J,Schulze K,Krech T,Ewald F,Nashan B,Pantel K,Lohse AW,Riethdorf S,Wege H.Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection.Oncotarget 2017;8:89978-89987[PMID:29163804 DOI:10.18632/oncotarget.21208]
107 Guo W,Sun YF,Shen MN,Ma XL,Wu J,Zhang CY,Zhou Y,Xu Y,Hu B,Zhang M,Wang G,Chen WQ,Guo L,Lu RQ,Zhou CH,Zhang X,Shi YH,Qiu SJ,Pan BS,Cao Y,Zhou J,Yang XR,Fan J.Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis,Prognosis,and Therapeutic Response Evaluation in Hepatocellular Carcinoma.Clin Cancer Res 2018;24:2203-2213[PMID:29374055 DOI:10.1158/1078-0432.CCR-17-1753]
108 Qi LN,Xiang BD,Wu FX,Ye JZ,Zhong JH,Wang YY,Chen YY,Chen ZS,Ma L,Chen J,Gong WF,Han ZG,Lu Y,Shang JJ,Li LQ.Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma.Cancer Res 2018;78:4731-4744[PMID:29915159 DOI:10.1158/0008-5472.CAN-17-2459]
109 Sun C,Liao W,Deng Z,Li E,Feng Q,Lei J,Yuan R,Zou S,Mao Y,Shao J,Wu L,Zhang C.The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma:A meta-analysis.Medicine(Baltimore)2017;96:e7513[PMID:28723763 DOI:10.1097/MD.0000000000007513]
110 Yin CQ,Yuan CH,Qu Z,Guan Q,Chen H,Wang FB.Liquid Biopsy of Hepatocellular Carcinoma:Circulating Tumor-Derived Biomarkers.Dis Markers 2016;2016:1427849[PMID:27403030 DOI:10.1155/2016/1427849]
111 Alvarez Cubero MJ,Lorente JA,Robles-Fernandez I,Rodriguez-Martinez A,Puche JL,Serrano MJ.Circulating Tumor Cells:Markers and Methodologies for Enrichment and Detection.Methods Mol Biol2017;1634:283-303[PMID:28819860 DOI:10.1007/978-1-4939-7144-2_24]
112 D'Avola D,Villacorta-Martin C,Martins-Filho SN,Craig A,Labgaa I,von Felden J,Kimaada A,Bonaccorso A,Tabrizian P,Hartmann BM,Sebra R,Schwartz M,Villanueva A.High-density single cell m RNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma.Sci Rep 2018;8:11570[PMID:30068984 DOI:10.1038/s41598-018-30047-y]
113 Chen J,Cao SW,Cai Z,Zheng L,Wang Q.Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients.Cancer Biomark 2017;20:487-498[PMID:28869439 DOI:10.3233/CBM-170315]
114 Li YM,Xu SC,Li J,Han KQ,Pi HF,Zheng L,Zuo GH,Huang XB,Li HY,Zhao HZ,Yu ZP,Zhou Z,Liang P.Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease.Cell Death Dis 2013;4:e831[PMID:24091674 DOI:10.1038/cddis.2013.347]
115 Vona G,Estepa L,Béroud C,Damotte D,Capron F,Nalpas B,Mineur A,Franco D,Lacour B,Pol S,Bréchot C,Paterlini-Bréchot P.Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer.Hepatology 2004;39:792-797[PMID:14999698 DOI:10.1002/hep.20091]
116 Lee S,Loecher M,Iyer R.Immunomodulation in hepatocellular cancer.J Gastrointest Oncol 2018;9:208-219[PMID:29564186 DOI:10.21037/jgo.2017.06.08]
117 Makarova-Rusher OV,Medina-Echeverz J,Duffy AG,Greten TF.The yin and yang of evasion and immune activation in HCC.J Hepatol 2015;62:1420-1429[PMID:25733155 DOI:10.1016/j.jhep.2015.02.038]
118 Nishida N,Kudo M.Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication.Oncology 2017;92 Suppl 1:40-49[PMID:27764823 DOI:10.1159/000451015]
119 Sachdeva M,Chawla YK,Arora SK.Immunology of hepatocellular carcinoma.World J Hepatol 2015;7:2080-2090[PMID:26301050 DOI:10.4254/wjh.v7.i17.2080]
120 Zhao F,Korangy F,Greten TF.Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma.Dig Dis 2012;30:477-482[PMID:23108303 DOI:10.1159/000341695]
121 Wellenstein MD,de Visser KE.Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape.Immunity 2018;48:399-416[PMID:29562192 DOI:10.1016/j.immuni.2018.03.004]
122 Lugade AA,Kalathil S,Miller A,Iyer R,Thanavala Y.High immunosuppressive burden in advanced hepatocellular carcinoma patients:Can effector functions be restored?Oncoimmunology 2013;2:e24679[PMID:24073364 DOI:10.4161/onci.24679]
123 Greten TF,Sangro B.Targets for immunotherapy of liver cancer.J Hepatol 2017[PMID:28923358 DOI:10.1016/j.jhep.2017.09.007]
124 Lin YY,Tan CT,Chen CW,Ou DL,Cheng AL,Hsu C.Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma:Implication for the Future of Immunotherapy.Semin Liver Dis2018;38:379-388[PMID:30357775 DOI:10.1055/s-0038-1673621]
125 Mukaida N,Nakamoto Y.Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.World J Gastroenterol 2018;24:1839-1858[PMID:29740200 DOI:10.3748/wjg.v24.i17.1839]
126 Cole SW.New challenges in psycho-oncology:Neural regulation of the cancer genome.Psychooncology2018;27:2305-2309[PMID:30022563 DOI:10.1002/pon.4838]
127 Dong T,Zhi L,Bhayana B,Wu MX.Cortisol-induced immune suppression by a blockade of lymphocyte egress in traumatic brain injury.J Neuroinflammation 2016;13:197[PMID:27561600 DOI:10.1186/s12974-016-0663-y]
128 Lang MJ,David V,Giese-Davis J.The Age Conundrum:A Scoping Review of Younger Age or Adolescent and Young Adult as a Risk Factor for Clinical Distress,Depression,or Anxiety in Cancer.JAdolesc Young Adult Oncol 2015;4:157-173[PMID:26697266 DOI:10.1089/jayao.2015.0005]
129 Idris SZ,Hassan N,Lee LJ,Md Noor S,Osman R,Abdul-Jalil M,Nordin AJ,Abdullah M.Increased regulatory T cells in acute lymphoblastic leukemia patients.Hematology 2015;20:523-529[PMID:26119924 DOI:10.1179/1607845415Y.0000000025]
130 Sephton SE,Lush E,Dedert EA,Floyd AR,Rebholz WN,Dhabhar FS,Spiegel D,Salmon P.Diurnal cortisol rhythm as a predictor of lung cancer survival.Brain Behav Immun 2013;30 Suppl:S163-S170[PMID:22884416 DOI:10.1016/j.bbi.2012.07.019]
131 Fabre B,Grosman H,Gonzalez D,Machulsky NF,Repetto EM,Mesch V,Lopez MA,Mazza O,Berg G.Prostate Cancer,High Cortisol Levels and Complex Hormonal Interaction.Asian Pac J Cancer Prev 2016;17:3167-3171[PMID:27509946]
132 Moreno-Smith M,Lutgendorf SK,Sood AK.Impact of stress on cancer metastasis.Future Oncol 2010;6:1863-1881[PMID:21142861 DOI:10.2217/fon.10.142]
133 Schrepf A,Thaker PH,Goodheart MJ,Bender D,Slavich GM,Dahmoush L,Penedo F,De Geest K,Mendez L,Lubaroff DM,Cole SW,Sood AK,Lutgendorf SK.Diurnal cortisol and survival in epithelial ovarian cancer.Psychoneuroendocrinology 2015;53:256-267[PMID:25647344 DOI:10.1016/j.psyneuen.2015.01.010]
134 Wu W,Liu S,Liang Y,Zhou Z,Bian W,Liu X.Stress Hormone Cortisol Enhances Bcl2 Like-12Expression to Inhibit p53 in Hepatocellular Carcinoma Cells.Dig Dis Sci 2017;62:3495-3500[PMID:29043595 DOI:10.1007/s10620-017-4798-1]
135 Webster S,Chandrasekaran S,Vijayaragavan R,Sethu G.Impact of Emotional Support on Serum Cortisol in Breast Cancer Patients.Indian J Palliat Care 2016;22:141-149[PMID:27162424 DOI:10.4103/0973-1075.179607]
136 Scerbo MJ,Gerdes JM.Bonding Withβ-Cells-A Role for Oxytocin in Glucose Handling.Diabetes 2017;66:256-257[PMID:28108604 DOI:10.2337/dbi16-0053]
137 Lerman B,Harricharran T,Ogunwobi OO.Oxytocin and cancer:An emerging link.World J Clin Oncol2018;9:74-82[PMID:30254962 DOI:10.5306/wjco.v9.i5.74]
138 Cassoni P,Sapino A,Fortunati N,Munaron L,Chini B,Bussolati G.Oxytocin inhibits the proliferation of MDA-MB231 human breast-cancer cells via cyclic adenosine monophosphate and protein kinase A.Int JCancer 1997;72:340-344[PMID:9219843]
139 Xu H,Fu S,Chen Q,Gu M,Zhou J,Liu C,Chen Y,Wang Z.The function of oxytocin:a potential biomarker for prostate cancer diagnosis and promoter of prostate cancer.Oncotarget 2017;8:31215-31226[PMID:28415720 DOI:10.18632/oncotarget.16107]
140 Mankarious A,Dave F,Pados G,Tsolakidis D,Gidron Y,Pang Y,Thomas P,Hall M,Karteris E.The pro-social neurohormone oxytocin reverses the actions of the stress hormone cortisol in human ovarian carcinoma cells in vitro.Int J Oncol 2016;48:1805-1814[PMID:26935408 DOI:10.3892/ijo.2016.3410]
141 Lindblad M,García Rodríguez LA,Chandanos E,Lagergren J.Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas.Br J Cancer 2006;94:136-141[PMID:16404367 DOI:10.1038/sj.bjc.6602906]
142 Skinner HG,Michaud DS,Colditz GA,Giovannucci EL,Stampfer MJ,Willett WC,Fuchs CS.Parity,reproductive factors,and the risk of pancreatic cancer in women.Cancer Epidemiol Biomarkers Prev2003;12:433-438[PMID:12750238]
2 Siegel RL,Miller KD,Jemal A.Cancer Statistics,2017.CA Cancer J Clin 2017;67:7-30[PMID:28055103 DOI:10.3322/caac.21387]
3 Ghouri YA,Mian I,Rowe JH.Review of hepatocellular carcinoma:Epidemiology,etiology,and carcinogenesis.J Carcinog 2017;16:1[PMID:28694740 DOI:10.4103/jcar.JCar_9_16]
4 Golabi P,Fazel S,Otgonsuren M,Sayiner M,Locklear CT,Younossi ZM.Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities.Medicine(Baltimore)2017;96:e5904[PMID:28248853 DOI:10.1097/MD.0000000000005904]
5 Medavaram S,Zhang Y.Emerging therapies in advanced hepatocellular carcinoma.Exp Hematol Oncol2018;7:17[PMID:30087805 DOI:10.1186/s40164-018-0109-6]
6 Siegel RL,Miller KD,Jemal A.Cancer statistics,2018.CA Cancer J Clin 2018;68:7-30[PMID:29313949 DOI:10.3322/caac.21442]
7 Dimitroulis D,Damaskos C,Valsami S,Davakis S,Garmpis N,Spartalis E,Athanasiou A,Moris D,Sakellariou S,Kykalos S,Tsourouflis G,Garmpi A,Delladetsima I,Kontzoglou K,Kouraklis G.From diagnosis to treatment of hepatocellular carcinoma:An epidemic problem for both developed and developing world.World J Gastroenterol 2017;23:5282-5294[PMID:28839428 DOI:10.3748/wjg.v23.i29.5282]
8 Daher S,Massarwa M,Benson AA,Khoury T.Current and Future Treatment of Hepatocellular Carcinoma:An Updated Comprehensive Review.J Clin Transl Hepatol 2018;6:69-78[PMID:29607307DOI:10.14218/JCTH.2017.00031]
9 Ikeda M,Morizane C,Ueno M,Okusaka T,Ishii H,Furuse J.Chemotherapy for hepatocellular carcinoma:current status and future perspectives.Jpn J Clin Oncol 2018;48:103-114[PMID:29253194DOI:10.1093/jjco/hyx180]
10 Keating GM.Sorafenib:A Review in Hepatocellular Carcinoma.Target Oncol 2017;12:243-253[PMID:28299600 DOI:10.1007/s11523-017-0484-7]
11 Sanz-Cameno P,Trapero-Marugán M,Chaparro M,Jones EA,Moreno-Otero R.Angiogenesis:from chronic liver inflammation to hepatocellular carcinoma.J Oncol 2010;2010:272170[PMID:20592752DOI:10.1155/2010/272170]
12 Sampat KR,O'Neil B.Antiangiogenic therapies for advanced hepatocellular carcinoma.Oncologist 2013;18:430-438[PMID:23576483 DOI:10.1634/theoncologist.2012-0388]
13 Personeni N,Pressiani T,Santoro A,Rimassa L.Regorafenib in hepatocellular carcinoma:latest evidence and clinical implications.Drugs Context 2018;7:212533[PMID:30002715 DOI:10.7573/dic.212533]
14 Spallanzani A,Orsi G,Andrikou K,Gelsomino F,Rimini M,Riggi L,Cascinu S.Lenvatinib as a therapy for unresectable hepatocellular carcinoma.Expert Rev Anticancer Ther 2018;18:1069-1076[PMID:30220234 DOI:10.1080/14737140.2018.1524297]
15 Dhanasekaran R,Bandoh S,Roberts LR.Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances.F1000Res 2016;5[PMID:27239288 DOI:10.12688/f1000research.6946.1]
16 Tarocchi M,Polvani S,Marroncini G,Galli A.Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis.World J Gastroenterol 2014;20:11630-11640[PMID:25206269 DOI:10.3748/wjg.v20.i33.11630]
17 Ortega-Prieto AM,Dorner M.Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection.Vaccines(Basel)2017;5[PMID:28862649 DOI:10.3390/vaccines5030024]
18 Ramakrishna G,Rastogi A,Trehanpati N,Sen B,Khosla R,Sarin SK.From cirrhosis to hepatocellular carcinoma:new molecular insights on inflammation and cellular senescence.Liver Cancer 2013;2:367-383[PMID:24400224 DOI:10.1159/000343852]
19 Bartosch B,Thimme R,Blum HE,Zoulim F.Hepatitis C virus-induced hepatocarcinogenesis.J Hepatol2009;51:810-820[PMID:19545926 DOI:10.1016/j.jhep.2009.05.008]
20 Alzahrani B,Iseli TJ,Hebbard LW.Non-viral causes of liver cancer:does obesity led inflammation play a role?Cancer Lett 2014;345:223-229[PMID:24007864 DOI:10.1016/j.canlet.2013.08.036]
21 Sorrentino P,D'Angelo S,Ferbo U,Micheli P,Bracigliano A,Vecchione R.Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis.J Hepatol 2009;50:351-357[PMID:19070395 DOI:10.1016/j.jhep.2008.09.011]
22 Hann HW,Kim CY,London WT,Blumberg BS.Increased serum ferritin in chronic liver disease:a risk factor for primary hepatocellular carcinoma.Int J Cancer 1989;43:376-379[PMID:2538399]
23 Asare GA,Bronz M,Naidoo V,Kew MC.Synergistic interaction between excess hepatic iron and alcohol ingestion in hepatic mutagenesis.Toxicology 2008;254:11-18[PMID:18852013 DOI:10.1016/j.tox.2008.08.024]
24 Siriwardana RC,Niriella MA,Dassanayake A,Ediriweera D,Gunetilleke B,Sivasundaram T,de Silva J.Association of Serum Ferritin with Diabetes and Alcohol in Patients with Non-Viral Liver Disease-Related Hepatocellular Carcinoma.Liver Cancer 2017;6:307-312[PMID:29234634 DOI:10.1159/000477266]
25 Campbell PT,Newton CC,Freedman ND,Koshiol J,Alavanja MC,Beane Freeman LE,Buring JE,Chan AT,Chong DQ,Datta M,Gaudet MM,Gaziano JM,Giovannucci EL,Graubard BI,Hollenbeck AR,King L,Lee IM,Linet MS,Palmer JR,Petrick JL,Poynter JN,Purdue MP,Robien K,Rosenberg L,Sahasrabuddhe VV,Schairer C,Sesso HD,Sigurdson AJ,Stevens VL,Wactawski-Wende J,ZeleniuchJacquotte A,Renehan AG,Mc Glynn KA.Body Mass Index,Waist Circumference,Diabetes,and Risk of Liver Cancer for U.S.Adults.Cancer Res 2016;76:6076-6083[PMID:27742674 DOI:10.1158/0008-5472.CAN-16-0787]
26 Wei L,Li N,Wang G,Feng X,Lyu Z,Li X,Wen Y,Chen Y,Chen H,Chen S,Wu S,Dai M,He J.Waist Circumference Might Be a Predictor of Primary Liver Cancer:A Population-Based Cohort Study.Front Oncol 2018;8:607[PMID:30631750 DOI:10.3389/fonc.2018.00607]
27 Hu M,Phan F,Bourron O,FerréP,Foufelle F.Steatosis and NASH in type 2 diabetes.Biochimie 2017;143:37-41[PMID:29097281 DOI:10.1016/j.biochi.2017.10.019]
28 Yan G,Wang X,Sun C,Zheng X,Wei H,Tian Z,Sun R.Chronic Alcohol Consumption Promotes Diethylnitrosamine-Induced Hepatocarcinogenesis via Immune Disturbances.Sci Rep 2017;7:2567[PMID:28566719 DOI:10.1038/s41598-017-02887-7]
29 Ramadori P,Cubero FJ,Liedtke C,Trautwein C,Nevzorova YA.Alcohol and Hepatocellular Carcinoma:Adding Fuel to the Flame.Cancers(Basel)2017;9[PMID:28946672 DOI:10.3390/cancers9100130]
30 Ogunwobi OO,Puszyk W,Dong HJ,Liu C.Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma.PLo S One 2013;8:e63765[PMID:23723997 DOI:10.1371/journal.pone.0063765]
31 Singh AK,Kumar R,Pandey AK.Hepatocellular Carcinoma:Causes,Mechanism of Progression and Biomarkers.Curr Chem Genom Transl Med 2018;12:9-26[PMID:30069430 DOI:10.2174/2213988501812010009]
32 Kew MC.Aflatoxins as a cause of hepatocellular carcinoma.J Gastrointestin Liver Dis 2013;22:305-310[PMID:24078988]
33 Wu HC,Santella R.The role of aflatoxins in hepatocellular carcinoma.Hepat Mon 2012;12:e7238[PMID:23162603 DOI:10.5812/hepatmon.7238]
34 Tansel A,Katz LH,El-Serag HB,Thrift AP,Parepally M,Shakhatreh MH,Kanwal F.Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis:A Systematic Review and Metaanalysis.Clin Gastroenterol Hepatol 2017;15:1207-1217.e4[PMID:28215616 DOI:10.1016/j.cgh.2017.02.006]
35 Llovet JM,Zucman-Rossi J,Pikarsky E,Sangro B,Schwartz M,Sherman M,Gores G.Hepatocellular carcinoma.Nat Rev Dis Primers 2016;2:16018[PMID:27158749 DOI:10.1038/nrdp.2016.18]
36 Llovet JM,Montal R,Sia D,Finn RS.Molecular therapies and precision medicine for hepatocellular carcinoma.Nat Rev Clin Oncol 2018;15:599-616[PMID:30061739 DOI:10.1038/s41571-018-0073-4]
37 Brabletz T,Kalluri R,Nieto MA,Weinberg RA.EMT in cancer.Nat Rev Cancer 2018;18:128-134[PMID:29326430 DOI:10.1038/nrc.2017.118]
38 Kalluri R,Weinberg RA.The basics of epithelial-mesenchymal transition.J Clin Invest 2009;119:1420-1428[PMID:19487818 DOI:10.1172/JCI39104]
39 Lamouille S,Xu J,Derynck R.Molecular mechanisms of epithelial-mesenchymal transition.Nat Rev Mol Cell Biol 2014;15:178-196[PMID:24556840 DOI:10.1038/nrm3758]
40 Ye X,Weinberg RA.Epithelial-Mesenchymal Plasticity:A Central Regulator of Cancer Progression.Trends Cell Biol 2015;25:675-686[PMID:26437589 DOI:10.1016/j.tcb.2015.07.012]
41 Huaman J,Bach C,Ilboudo A,Ogunwobi OO,Liu C.Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma.Liu C.Precision Molecular Pathology of Liver Cancer.Cham:Springer International Publishing 2018;131-152
42 Puisieux A,Brabletz T,Caramel J.Oncogenic roles of EMT-inducing transcription factors.Nat Cell Biol2014;16:488-494[PMID:24875735 DOI:10.1038/ncb2976]
43 Tiwari N,Gheldof A,Tatari M,Christofori G.EMT as the ultimate survival mechanism of cancer cells.Semin Cancer Biol 2012;22:194-207[PMID:22406545 DOI:10.1016/j.semcancer.2012.02.013]
44 Chen L,Guo P,He Y,Chen Z,Chen L,Luo Y,Qi L,Liu Y,Wu Q,Cui Y,Fang F,Zhang X,Song T,Guo H.HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway.Cell Death Dis 2018;9:513[PMID:29725020 DOI:10.1038/s41419-018-0534-9]
45 Long L,Xiang H,Liu J,Zhang Z,Sun L.ZEB1 mediates doxorubicin(Dox)resistance and mesenchymal characteristics of hepatocarcinoma cells.Exp Mol Pathol 2019;106:116-122[PMID:30615851 DOI:10.1016/j.yexmp.2019.01.001]
46 Qu W,Wen X,Su K,Gou W.Mi R-552 promotes the proliferation,migration and EMT of hepatocellular carcinoma cells by inhibiting AJAP1 expression.J Cell Mol Med 2019;23:1541-1552[PMID:30597727DOI:10.1111/jcmm.14062]
47 Shi C,Chen Y,Chen Y,Yang Y,Bing W,Qi J.CD4+CD25+regulatory T cells promote hepatocellular carcinoma invasion via TGF-β1-induced epithelial-mesenchymal transition.Onco Targets Ther 2018;12:279-289[PMID:30643426 DOI:10.2147/OTT.S172417]
48 Xia C,Zhang XY,Liu W,Ju M,Ju Y,Bu YZ,Wang W,Shao H.LINC00857 contributes to hepatocellular carcinoma malignancy via enhancing epithelial-mesenchymal transition.J Cell Biochem2018[PMID:30506763 DOI:10.1002/jcb.28074]
49 Zhang B,Shi D,Zhang X,Liang G,Liu W,Qiao S.FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells.Oncol Lett 2018;16:7231-7238[PMID:30546461 DOI:10.3892/ol.2018.9541]
50 Das DK,Durojaiye V,Ilboudo A,Naidoo MK,Ogunwobi O.A"Patient-Like"Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis.J Vis Exp 2015;e52858[PMID:26555484 DOI:10.3791/52858]
51 Yang JD,Nakamura I,Roberts LR.The tumor microenvironment in hepatocellular carcinoma:current status and therapeutic targets.Semin Cancer Biol 2011;21:35-43[PMID:20946957 DOI:10.1016/j.semcancer.2010.10.007]
52 Delire B,Henriet P,Lemoine P,Leclercq IA,St?rkel P.Chronic liver injury promotes hepatocarcinoma cell seeding and growth,associated with infiltration by macrophages.Cancer Sci 2018;109:2141-2152[PMID:29727510 DOI:10.1111/cas.13628]
53 Affo S,Yu LX,Schwabe RF.The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer.Annu Rev Pathol 2017;12:153-186[PMID:27959632 DOI:10.1146/annurev-pathol-052016-100322]
54 Lu Y,Lin N,Chen Z,Xu R.Hypoxia-induced secretion of platelet-derived growth factor-BB by hepatocellular carcinoma cells increases activated hepatic stellate cell proliferation,migration and expression of vascular endothelial growth factor-A.Mol Med Rep 2015;11:691-697[PMID:25333351DOI:10.3892/mmr.2014.2689]
55 GalièM,Sorrentino C,Montani M,Micossi L,Di Carlo E,D'Antuono T,Calderan L,Marzola P,Benati D,Merigo F,Orlando F,Smorlesi A,Marchini C,Amici A,Sbarbati A.Mammary carcinoma provides highly tumourigenic and invasive reactive stromal cells.Carcinogenesis 2005;26:1868-1878[PMID:15975963 DOI:10.1093/carcin/bgi158]
56 Hernandez-Gea V,Toffanin S,Friedman SL,Llovet JM.Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.Gastroenterology 2013;144:512-527[PMID:23313965 DOI:10.1053/j.gastro.2013.01.002]
57 Friedman SL.Mechanisms of hepatic fibrogenesis.Gastroenterology 2008;134:1655-1669[PMID:18471545 DOI:10.1053/j.gastro.2008.03.003]
58 Amann T,Bataille F,Spruss T,Mühlbauer M,G?bele E,Sch?lmerich J,Kiefer P,Bosserhoff AK,Hellerbrand C.Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma.Cancer Sci 2009;100:646-653[PMID:19175606 DOI:10.1111/j.1349-7006.2009.01087.x]
59 Faouzi S,Lepreux S,Bedin C,Dubuisson L,Balabaud C,Bioulac-Sage P,Desmoulière A,Rosenbaum J.Activation of cultured rat hepatic stellate cells by tumoral hepatocytes.Lab Invest 1999;79:485-493[PMID:10212001]
60 Wang N,Wang S,Li MY,Hu BG,Liu LP,Yang SL,Yang S,Gong Z,Lai PBS,Chen GG.Cancer stem cells in hepatocellular carcinoma:an overview and promising therapeutic strategies.Ther Adv Med Oncol2018;10:1758835918816287[PMID:30622654 DOI:10.1177/1758835918816287]
61 Fransvea E,Paradiso A,Antonaci S,Giannelli G.HCC heterogeneity:molecular pathogenesis and clinical implications.Cell Oncol 2009;31:227-233[PMID:19478390 DOI:10.3233/CLO-2009-0473]
62 Williams GM,Gebhardt R,Sirma H,Stenb?ck F.Non-linearity of neoplastic conversion induced in rat liver by low exposures to diethylnitrosamine.Carcinogenesis 1993;14:2149-2156[PMID:8106178]
63 Bralet MP,Pichard V,Ferry N.Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosamine-treated rats.Hepatology 2002;36:623-630[PMID:12198654 DOI:10.1053/jhep.2002.35540]
64 Wu S,Powers S,Zhu W,Hannun YA.Substantial contribution of extrinsic risk factors to cancer development.Nature 2016;529:43-47[PMID:26675728 DOI:10.1038/nature16166]
65 Yavorkovsky L,Lai E,Ilic Z,Sell S.Participation of small intraportal stem cells in the restitutive response of the liver to periportal necrosis induced by allyl alcohol.Hepatology 1995;21:1702-1712[PMID:7539398]
66 Zhang Y,Bai XF,Huang CX.Hepatic stem cells:existence and origin.World J Gastroenterol 2003;9:201-204[PMID:12532431]
67 Mikhail S,He AR.Liver cancer stem cells.Int J Hepatol 2011;2011:486954[PMID:21994859 DOI:10.4061/2011/486954]
68 Jayachandran A,Dhungel B,Steel JC.Epithelial-to-mesenchymal plasticity of cancer stem cells:therapeutic targets in hepatocellular carcinoma.J Hematol Oncol 2016;9:74[PMID:27578206 DOI:10.1186/s13045-016-0307-9]
69 Machida K.Existence of cancer stem cells in hepatocellular carcinoma:myth or reality?Hepatol Int2017;11:143-147[PMID:27990610 DOI:10.1007/s12072-016-9777-7]
70 Jordan CT,Guzman ML,Noble M.Cancer stem cells.N Engl J Med 2006;355:1253-1261[PMID:16990388 DOI:10.1056/NEJMra061808]
71 Bonnet D,Dick JE.Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.Nat Med 1997;3:730-737[PMID:9212098]
72 Lapidot T,Sirard C,Vormoor J,Murdoch B,Hoang T,Caceres-Cortes J,Minden M,Paterson B,Caligiuri MA,Dick JE.A cell initiating human acute myeloid leukaemia after transplantation into SCIDmice.Nature 1994;367:645-648[PMID:7509044 DOI:10.1038/367645a0]
73 Cabrera MC,Hollingsworth RE,Hurt EM.Cancer stem cell plasticity and tumor hierarchy.World J Stem Cells 2015;7:27-36[PMID:25621103 DOI:10.4252/wjsc.v7.i1.27]
74 Pattabiraman DR,Weinberg RA.Tackling the cancer stem cells-what challenges do they pose?Nat Rev Drug Discov 2014;13:497-512[PMID:24981363 DOI:10.1038/nrd4253]
75 Thiery JP.Epithelial-mesenchymal transitions in tumour progression.Nat Rev Cancer 2002;2:442-454[PMID:12189386 DOI:10.1038/nrc822]
76 Wang T,Shigdar S,Gantier MP,Hou Y,Wang L,Li Y,Shamaileh HA,Yin W,Zhou SF,Zhao X,Duan W.Cancer stem cell targeted therapy:progress amid controversies.Oncotarget 2015;6:44191-44206[PMID:26496035 DOI:10.18632/oncotarget.6176]
77 Vu NB,Nguyen TT,Tran LC,Do CD,Nguyen BH,Phan NK,Pham PV.Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties.Cytotechnology 2013;65:491-503[PMID:23104270 DOI:10.1007/s10616-012-9511-9]
78 Rao S,Zaidi S,Banerjee J,Jogunoori W,Sebastian R,Mishra B,Nguyen BN,Wu RC,White J,Deng C,Amdur R,Li S,Mishra L.Transforming growth factor-βin liver cancer stem cells and regeneration.Hepatol Commun 2017;1:477-493[PMID:29404474 DOI:10.1002/hep4.1062]
79 Nio K,Yamashita T,Kaneko S.The evolving concept of liver cancer stem cells.Mol Cancer 2017;16:4[PMID:28137313 DOI:10.1186/s12943-016-0572-9]
80 Yoon SK.The biology of cancer stem cells and its clinical implication in hepatocellular carcinoma.Gut Liver 2012;6:29-40[PMID:22375168 DOI:10.5009/gnl.2012.6.1.29]
81 Yamashita T,Ji J,Budhu A,Forgues M,Yang W,Wang HY,Jia H,Ye Q,Qin LX,Wauthier E,Reid LM,Minato H,Honda M,Kaneko S,Tang ZY,Wang XW.Ep CAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features.Gastroenterology 2009;136:1012-1024[PMID:19150350 DOI:10.1053/j.gastro.2008.12.004]
82 Yang ZF,Ho DW,Ng MN,Lau CK,Yu WC,Ngai P,Chu PW,Lam CT,Poon RT,Fan ST.Significance of CD90+cancer stem cells in human liver cancer.Cancer Cell 2008;13:153-166[PMID:18242515DOI:10.1016/j.ccr.2008.01.013]
83 Ma S,Chan KW,Hu L,Lee TK,Wo JY,Ng IO,Zheng BJ,Guan XY.Identification and characterization of tumorigenic liver cancer stem/progenitor cells.Gastroenterology 2007;132:2542-2556[PMID:17570225 DOI:10.1053/j.gastro.2007.04.025]
84 Zhu Z,Hao X,Yan M,Yao M,Ge C,Gu J,Li J.Cancer stem/progenitor cells are highly enriched in CD133+CD44+population in hepatocellular carcinoma.Int J Cancer 2010;126:2067-2078[PMID:19711346 DOI:10.1002/ijc.24868]
85 Haraguchi N,Ishii H,Mimori K,Tanaka F,Ohkuma M,Kim HM,Akita H,Takiuchi D,Hatano H,Nagano H,Barnard GF,Doki Y,Mori M.CD13 is a therapeutic target in human liver cancer stem cells.JClin Invest 2010;120:3326-3339[PMID:20697159 DOI:10.1172/JCI42550]
86 Merle P,Trepo C.Molecular mechanisms underlying hepatocellular carcinoma.Viruses 2009;1:852-872[PMID:21994573 DOI:10.3390/v1030852]
87 Di Micco R,Fumagalli M,Cicalese A,Piccinin S,Gasparini P,Luise C,Schurra C,Garre'M,Nuciforo PG,Bensimon A,Maestro R,Pelicci PG,d'Adda di Fagagna F.Oncogene-induced senescence is a DNAdamage response triggered by DNA hyper-replication.Nature 2006;444:638-642[PMID:17136094 DOI:10.1038/nature05327]
88 Naugler WE,Karin M.NF-kappa B and cancer-identifying targets and mechanisms.Curr Opin Genet Dev2008;18:19-26[PMID:18440219 DOI:10.1016/j.gde.2008.01.020]
89 Van Antwerp DJ,Martin SJ,Kafri T,Green DR,Verma IM.Suppression of TNF-alpha-induced apoptosis by NF-kappa B.Science 1996;274:787-789[PMID:8864120]
90 Bassères DS,Baldwin AS.Nuclear factor-kappa B and inhibitor of kappa B kinase pathways in oncogenic initiation and progression.Oncogene 2006;25:6817-6830[PMID:17072330 DOI:10.1038/sj.onc.1209942]
91 Luo JL,Tan W,Ricono JM,Korchynskyi O,Zhang M,Gonias SL,Cheresh DA,Karin M.Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin.Nature 2007;446:690-694[PMID:17377533 DOI:10.1038/nature05656]
92 Hardy T,Mann DA.Epigenetics in liver disease:from biology to therapeutics.Gut 2016;65:1895-1905[PMID:27624887 DOI:10.1136/gutjnl-2015-311292]
93 Xiao Z,Shen J,Zhang L,Li M,Hu W,Cho C.Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma:Recent progress and future prospects.Oncol Lett 2018;15:3395-3402[PMID:29467864 DOI:10.3892/ol.2018.7758]
94 Peng L,Yuan XQ,Zhang CY,Peng JY,Zhang YQ,Pan X,Li GC.The emergence of long non-coding RNAs in hepatocellular carcinoma:an update.J Cancer 2018;9:2549-2558[PMID:30026854 DOI:10.7150/jca.24560]
95 Sia D,Villanueva A,Friedman SL,Llovet JM.Liver Cancer Cell of Origin,Molecular Class,and Effects on Patient Prognosis.Gastroenterology 2017;152:745-761[PMID:28043904 DOI:10.1053/j.gastro.2016.11.048]
96 LetouzéE,Shinde J,Renault V,Couchy G,Blanc JF,Tubacher E,Bayard Q,Bacq D,Meyer V,Semhoun J,Bioulac-Sage P,Prév?t S,Azoulay D,Paradis V,Imbeaud S,Deleuze JF,Zucman-Rossi J.Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis.Nat Commun 2017;8:1315[PMID:29101368 DOI:10.1038/s41467-017-01358-x]
97 Hagel M,Miduturu C,Sheets M,Rubin N,Weng W,Stransky N,Bifulco N,Kim JL,Hodous B,Brooijmans N,Shutes A,Winter C,Lengauer C,Kohl NE,Guzi T.First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.Cancer Discov 2015;5:424-437[PMID:25776529 DOI:10.1158/2159-8290.CD-14-1029]
98 Micalizzi DS,Maheswaran S,Haber DA.A conduit to metastasis:circulating tumor cell biology.Genes Dev 2017;31:1827-1840[PMID:29051388 DOI:10.1101/gad.305805.117]
99 Gallerani G,Fici P,Fabbri F.Circulating Tumor Cells:Back to the Future.Front Oncol 2017;6:275[PMID:28123996 DOI:10.3389/fonc.2016.00275]
100 van de Stolpe A,Pantel K,Sleijfer S,Terstappen LW,den Toonder JM.Circulating tumor cell isolation and diagnostics:toward routine clinical use.Cancer Res 2011;71:5955-5960[PMID:21896640 DOI:10.1158/0008-5472.CAN-11-1254]
101 Pantel K,Brakenhoff RH,Brandt B.Detection,clinical relevance and specific biological properties of disseminating tumour cells.Nat Rev Cancer 2008;8:329-340[PMID:18404148 DOI:10.1038/nrc2375]
102 Fan JL,Yang YF,Yuan CH,Chen H,Wang FB.Circulating Tumor Cells for Predicting the Prognostic of Patients with Hepatocellular Carcinoma:A Meta Analysis.Cell Physiol Biochem 2015;37:629-640[PMID:26344495 DOI:10.1159/000430382]
103 Li J,Han X,Yu X,Xu Z,Yang G,Liu B,Xiu P.Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma:circulating tumor cells and circulating tumor DNA.JExp Clin Cancer Res 2018;37:213[PMID:30176913 DOI:10.1186/s13046-018-0893-1]
104 Okajima W,Komatsu S,Ichikawa D,Miyamae M,Ohashi T,Imamura T,Kiuchi J,Nishibeppu K,Arita T,Konishi H,Shiozaki A,Morimura R,Ikoma H,Okamoto K,Otsuji E.Liquid biopsy in patients with hepatocellular carcinoma:Circulating tumor cells and cell-free nucleic acids.World J Gastroenterol 2017;23:5650-5668[PMID:28883691 DOI:10.3748/wjg.v23.i31.5650]
105 Schulze K,Gasch C,Staufer K,Nashan B,Lohse AW,Pantel K,Riethdorf S,Wege H.Presence of Ep CAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.Int J Cancer 2013;133:2165-2171[PMID:23616258 DOI:10.1002/ijc.28230]
106 von Felden J,Schulze K,Krech T,Ewald F,Nashan B,Pantel K,Lohse AW,Riethdorf S,Wege H.Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection.Oncotarget 2017;8:89978-89987[PMID:29163804 DOI:10.18632/oncotarget.21208]
107 Guo W,Sun YF,Shen MN,Ma XL,Wu J,Zhang CY,Zhou Y,Xu Y,Hu B,Zhang M,Wang G,Chen WQ,Guo L,Lu RQ,Zhou CH,Zhang X,Shi YH,Qiu SJ,Pan BS,Cao Y,Zhou J,Yang XR,Fan J.Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis,Prognosis,and Therapeutic Response Evaluation in Hepatocellular Carcinoma.Clin Cancer Res 2018;24:2203-2213[PMID:29374055 DOI:10.1158/1078-0432.CCR-17-1753]
108 Qi LN,Xiang BD,Wu FX,Ye JZ,Zhong JH,Wang YY,Chen YY,Chen ZS,Ma L,Chen J,Gong WF,Han ZG,Lu Y,Shang JJ,Li LQ.Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma.Cancer Res 2018;78:4731-4744[PMID:29915159 DOI:10.1158/0008-5472.CAN-17-2459]
109 Sun C,Liao W,Deng Z,Li E,Feng Q,Lei J,Yuan R,Zou S,Mao Y,Shao J,Wu L,Zhang C.The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma:A meta-analysis.Medicine(Baltimore)2017;96:e7513[PMID:28723763 DOI:10.1097/MD.0000000000007513]
110 Yin CQ,Yuan CH,Qu Z,Guan Q,Chen H,Wang FB.Liquid Biopsy of Hepatocellular Carcinoma:Circulating Tumor-Derived Biomarkers.Dis Markers 2016;2016:1427849[PMID:27403030 DOI:10.1155/2016/1427849]
111 Alvarez Cubero MJ,Lorente JA,Robles-Fernandez I,Rodriguez-Martinez A,Puche JL,Serrano MJ.Circulating Tumor Cells:Markers and Methodologies for Enrichment and Detection.Methods Mol Biol2017;1634:283-303[PMID:28819860 DOI:10.1007/978-1-4939-7144-2_24]
112 D'Avola D,Villacorta-Martin C,Martins-Filho SN,Craig A,Labgaa I,von Felden J,Kimaada A,Bonaccorso A,Tabrizian P,Hartmann BM,Sebra R,Schwartz M,Villanueva A.High-density single cell m RNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma.Sci Rep 2018;8:11570[PMID:30068984 DOI:10.1038/s41598-018-30047-y]
113 Chen J,Cao SW,Cai Z,Zheng L,Wang Q.Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients.Cancer Biomark 2017;20:487-498[PMID:28869439 DOI:10.3233/CBM-170315]
114 Li YM,Xu SC,Li J,Han KQ,Pi HF,Zheng L,Zuo GH,Huang XB,Li HY,Zhao HZ,Yu ZP,Zhou Z,Liang P.Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease.Cell Death Dis 2013;4:e831[PMID:24091674 DOI:10.1038/cddis.2013.347]
115 Vona G,Estepa L,Béroud C,Damotte D,Capron F,Nalpas B,Mineur A,Franco D,Lacour B,Pol S,Bréchot C,Paterlini-Bréchot P.Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer.Hepatology 2004;39:792-797[PMID:14999698 DOI:10.1002/hep.20091]
116 Lee S,Loecher M,Iyer R.Immunomodulation in hepatocellular cancer.J Gastrointest Oncol 2018;9:208-219[PMID:29564186 DOI:10.21037/jgo.2017.06.08]
117 Makarova-Rusher OV,Medina-Echeverz J,Duffy AG,Greten TF.The yin and yang of evasion and immune activation in HCC.J Hepatol 2015;62:1420-1429[PMID:25733155 DOI:10.1016/j.jhep.2015.02.038]
118 Nishida N,Kudo M.Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication.Oncology 2017;92 Suppl 1:40-49[PMID:27764823 DOI:10.1159/000451015]
119 Sachdeva M,Chawla YK,Arora SK.Immunology of hepatocellular carcinoma.World J Hepatol 2015;7:2080-2090[PMID:26301050 DOI:10.4254/wjh.v7.i17.2080]
120 Zhao F,Korangy F,Greten TF.Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma.Dig Dis 2012;30:477-482[PMID:23108303 DOI:10.1159/000341695]
121 Wellenstein MD,de Visser KE.Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape.Immunity 2018;48:399-416[PMID:29562192 DOI:10.1016/j.immuni.2018.03.004]
122 Lugade AA,Kalathil S,Miller A,Iyer R,Thanavala Y.High immunosuppressive burden in advanced hepatocellular carcinoma patients:Can effector functions be restored?Oncoimmunology 2013;2:e24679[PMID:24073364 DOI:10.4161/onci.24679]
123 Greten TF,Sangro B.Targets for immunotherapy of liver cancer.J Hepatol 2017[PMID:28923358 DOI:10.1016/j.jhep.2017.09.007]
124 Lin YY,Tan CT,Chen CW,Ou DL,Cheng AL,Hsu C.Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma:Implication for the Future of Immunotherapy.Semin Liver Dis2018;38:379-388[PMID:30357775 DOI:10.1055/s-0038-1673621]
125 Mukaida N,Nakamoto Y.Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.World J Gastroenterol 2018;24:1839-1858[PMID:29740200 DOI:10.3748/wjg.v24.i17.1839]
126 Cole SW.New challenges in psycho-oncology:Neural regulation of the cancer genome.Psychooncology2018;27:2305-2309[PMID:30022563 DOI:10.1002/pon.4838]
127 Dong T,Zhi L,Bhayana B,Wu MX.Cortisol-induced immune suppression by a blockade of lymphocyte egress in traumatic brain injury.J Neuroinflammation 2016;13:197[PMID:27561600 DOI:10.1186/s12974-016-0663-y]
128 Lang MJ,David V,Giese-Davis J.The Age Conundrum:A Scoping Review of Younger Age or Adolescent and Young Adult as a Risk Factor for Clinical Distress,Depression,or Anxiety in Cancer.JAdolesc Young Adult Oncol 2015;4:157-173[PMID:26697266 DOI:10.1089/jayao.2015.0005]
129 Idris SZ,Hassan N,Lee LJ,Md Noor S,Osman R,Abdul-Jalil M,Nordin AJ,Abdullah M.Increased regulatory T cells in acute lymphoblastic leukemia patients.Hematology 2015;20:523-529[PMID:26119924 DOI:10.1179/1607845415Y.0000000025]
130 Sephton SE,Lush E,Dedert EA,Floyd AR,Rebholz WN,Dhabhar FS,Spiegel D,Salmon P.Diurnal cortisol rhythm as a predictor of lung cancer survival.Brain Behav Immun 2013;30 Suppl:S163-S170[PMID:22884416 DOI:10.1016/j.bbi.2012.07.019]
131 Fabre B,Grosman H,Gonzalez D,Machulsky NF,Repetto EM,Mesch V,Lopez MA,Mazza O,Berg G.Prostate Cancer,High Cortisol Levels and Complex Hormonal Interaction.Asian Pac J Cancer Prev 2016;17:3167-3171[PMID:27509946]
132 Moreno-Smith M,Lutgendorf SK,Sood AK.Impact of stress on cancer metastasis.Future Oncol 2010;6:1863-1881[PMID:21142861 DOI:10.2217/fon.10.142]
133 Schrepf A,Thaker PH,Goodheart MJ,Bender D,Slavich GM,Dahmoush L,Penedo F,De Geest K,Mendez L,Lubaroff DM,Cole SW,Sood AK,Lutgendorf SK.Diurnal cortisol and survival in epithelial ovarian cancer.Psychoneuroendocrinology 2015;53:256-267[PMID:25647344 DOI:10.1016/j.psyneuen.2015.01.010]
134 Wu W,Liu S,Liang Y,Zhou Z,Bian W,Liu X.Stress Hormone Cortisol Enhances Bcl2 Like-12Expression to Inhibit p53 in Hepatocellular Carcinoma Cells.Dig Dis Sci 2017;62:3495-3500[PMID:29043595 DOI:10.1007/s10620-017-4798-1]
135 Webster S,Chandrasekaran S,Vijayaragavan R,Sethu G.Impact of Emotional Support on Serum Cortisol in Breast Cancer Patients.Indian J Palliat Care 2016;22:141-149[PMID:27162424 DOI:10.4103/0973-1075.179607]
136 Scerbo MJ,Gerdes JM.Bonding Withβ-Cells-A Role for Oxytocin in Glucose Handling.Diabetes 2017;66:256-257[PMID:28108604 DOI:10.2337/dbi16-0053]
137 Lerman B,Harricharran T,Ogunwobi OO.Oxytocin and cancer:An emerging link.World J Clin Oncol2018;9:74-82[PMID:30254962 DOI:10.5306/wjco.v9.i5.74]
138 Cassoni P,Sapino A,Fortunati N,Munaron L,Chini B,Bussolati G.Oxytocin inhibits the proliferation of MDA-MB231 human breast-cancer cells via cyclic adenosine monophosphate and protein kinase A.Int JCancer 1997;72:340-344[PMID:9219843]
139 Xu H,Fu S,Chen Q,Gu M,Zhou J,Liu C,Chen Y,Wang Z.The function of oxytocin:a potential biomarker for prostate cancer diagnosis and promoter of prostate cancer.Oncotarget 2017;8:31215-31226[PMID:28415720 DOI:10.18632/oncotarget.16107]
140 Mankarious A,Dave F,Pados G,Tsolakidis D,Gidron Y,Pang Y,Thomas P,Hall M,Karteris E.The pro-social neurohormone oxytocin reverses the actions of the stress hormone cortisol in human ovarian carcinoma cells in vitro.Int J Oncol 2016;48:1805-1814[PMID:26935408 DOI:10.3892/ijo.2016.3410]
141 Lindblad M,García Rodríguez LA,Chandanos E,Lagergren J.Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas.Br J Cancer 2006;94:136-141[PMID:16404367 DOI:10.1038/sj.bjc.6602906]
142 Skinner HG,Michaud DS,Colditz GA,Giovannucci EL,Stampfer MJ,Willett WC,Fuchs CS.Parity,reproductive factors,and the risk of pancreatic cancer in women.Cancer Epidemiol Biomarkers Prev2003;12:433-438[PMID:12750238]